WO2003057149A3 - 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones - Google Patents

4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones Download PDF

Info

Publication number
WO2003057149A3
WO2003057149A3 PCT/US2002/041428 US0241428W WO03057149A3 WO 2003057149 A3 WO2003057149 A3 WO 2003057149A3 US 0241428 W US0241428 W US 0241428W WO 03057149 A3 WO03057149 A3 WO 03057149A3
Authority
WO
WIPO (PCT)
Prior art keywords
fused
heteropyrimidines
pyrimidones
hetero
substituted
Prior art date
Application number
PCT/US2002/041428
Other languages
French (fr)
Other versions
WO2003057149B1 (en
WO2003057149A2 (en
Inventor
William J Scott
Donald E Bierer
Andreas Stolle
Yuanwei Chen
Original Assignee
Bayer Ag
William J Scott
Donald E Bierer
Andreas Stolle
Yuanwei Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, William J Scott, Donald E Bierer, Andreas Stolle, Yuanwei Chen filed Critical Bayer Ag
Priority to AU2002360774A priority Critical patent/AU2002360774A1/en
Publication of WO2003057149A2 publication Critical patent/WO2003057149A2/en
Publication of WO2003057149A3 publication Critical patent/WO2003057149A3/en
Publication of WO2003057149B1 publication Critical patent/WO2003057149B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones, pharmaceutical compositions containing the same and their use to treat or prevent diseases and conditions mediated by the phosphodiesterase enzyme 7B (PDE7B). Diseases and conditions mediated by PDE7B include osteoporosis, osteopenia and asthma. The invention also relates to processes for preparing 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones and processes for preparing compositions containing the same.
PCT/US2002/041428 2001-12-28 2002-12-27 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones WO2003057149A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002360774A AU2002360774A1 (en) 2001-12-28 2002-12-27 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34415501P 2001-12-28 2001-12-28
US60/344,155 2001-12-28

Publications (3)

Publication Number Publication Date
WO2003057149A2 WO2003057149A2 (en) 2003-07-17
WO2003057149A3 true WO2003057149A3 (en) 2003-12-18
WO2003057149B1 WO2003057149B1 (en) 2004-02-19

Family

ID=23349286

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/041428 WO2003057149A2 (en) 2001-12-28 2002-12-27 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones

Country Status (2)

Country Link
AU (1) AU2002360774A1 (en)
WO (1) WO2003057149A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2280040T3 (en) * 2003-07-24 2007-09-01 Bayer Pharmaceuticals Corporation TETRAHYDROBENZOTIENOPIRIMIDINAMINE COMPOUNDS USEFUL REPLACED TO TREAT HYPERPROLIFERATIVE DISORDERS.
BRPI0809244A2 (en) 2007-03-27 2014-09-23 Omeros Corp METHODS OF TREATMENT OF A MOVEMENT ABNORMALITY, AND FOR IDENTIFYING AN AGENT INHIBITING PDE7 ACTIVITY.
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2009104026A1 (en) * 2008-02-19 2009-08-27 Vichem Chemie Kutató Kft Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
AU2011326173B2 (en) 2010-11-08 2015-08-27 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
WO2012097013A1 (en) 2011-01-10 2012-07-19 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN103562208B (en) 2011-03-15 2016-08-31 默沙东公司 Three ring gyrase inhibitors
TW201728592A (en) 2012-01-10 2017-08-16 林伯士艾瑞斯公司 IRAK inhibitors and uses thereof
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014011906A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP2892534B8 (en) * 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN105142639A (en) 2013-01-10 2015-12-09 林伯士艾瑞斯公司 IRAK inhibitors and uses thereof
EP3049086A4 (en) 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2023212019A1 (en) * 2022-04-28 2023-11-02 Enanta Pharmaceuticals, Inc. Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6140332A (en) * 1995-07-06 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6140332A (en) * 1995-07-06 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof

Also Published As

Publication number Publication date
WO2003057149B1 (en) 2004-02-19
AU2002360774A1 (en) 2003-07-24
WO2003057149A2 (en) 2003-07-17
AU2002360774A8 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
HUS1700003I1 (en) Pyrimidineamines as angiogenesis modulators and pharmaceutical compositions containing them
WO2005046603A3 (en) Pyridine compounds
WO2003057149A3 (en) 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
WO2002072570A3 (en) Non-imidazole compounds as histamine h3 antagonists
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2002064594A3 (en) 6-substituted pyrido-pyrimidines
HUP0304054A2 (en) Fused pyrimidines as antagonists of the corticotropin releasing factor (crf), process for their preparation and pharmaceutical compositions containing them
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
WO2002076979A8 (en) 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
WO2002032893A3 (en) Piperidine compounds as anti-allergic
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
MXPA03007983A (en) Process for the preparation of middle distillates.
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
IL161857A0 (en) Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
WO2005063764A3 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
WO2004106322A3 (en) Polymorphs of aripiprazole
HUP0303813A3 (en) Arylsulfonamides as antiviral agents, process for preparation of the compounds and pharmaceutical compositions containing them
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
WO2002024695A3 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
WO2003037863A3 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
WO2003072541A3 (en) Chemical compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20030825

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP